Alosetron and irritable bowel syndrome

Bibliography

• CUBEDDU LX, HOFFMANN IS,FUENMAYOR NT et al.: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl. J. Med. (1990) 322:810–816.
   Google Scholar
• MARTY M, POUILLART P,SCHOLL S et al: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl. I Med. (1990) 322:816–821.
   PubMed Web of Science ®Google Scholar
• OLIVIER B, VAN WIJNGAARDEN I, SOUDIJN W: 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review. Eur. Neuropsychopharmacol (2000) 10:77–95.
   PubMed Web of Science ®Google Scholar
• FARIS PL, KIM SW, MELLER WH et al: Effect of ondansetron, a 5-HT3R antagonist, on the dynamic associationbetween bulimic behaviors and painthresholds. Pain (1998) 77:297–303.
   PubMedGoogle Scholar
• ROME II: The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus, (2'd edn). McLean VA: Degnon Associates. (2000).
   Google Scholar
• GRALNEK IM, HAYS RD, KILBOURNE A et al: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology(2000) 119:654–660.
   PubMed Web of Science ®Google Scholar
• BADIA X, MEARIN F, BALBOA A et al.:Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics (2002) 20:749–758.
   PubMed Web of Science ®Google Scholar
• CREMONINI F, DELGADO-AROS S, CAMILLERI M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Mod]. (2003) 15:79–86.
   PubMed Web of Science ®Google Scholar
• ••An important meta-analysis ofrandomised, controlled trials including six large, multi-centre studies showing the effect of alosetron on adequate relief ofpain or global improvement of symptoms in IBS patients.
   Google Scholar
• MAYER EA, COLLINS SM: Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology (2002) 122:2032–2048.
   PubMed Web of Science ®Google Scholar
• RACKE K, SCHWORER H: Regulation of serotonin release from the intestinal mucosa. Pharmacol Res. (1991) 23:13–25.
   PubMedGoogle Scholar
• MAWE GM, BRANCHEK TA, GERSHON MD: Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc. Natl. Acad. Sci. USA (1986) 83:9799–9803.
   PubMed Web of Science ®Google Scholar
• DERKACH V, SURPRENANT A, NORTH RA: 5-HT3Rs are membrane ion channels. Nature (1989) 339:706–709.
   PubMed Web of Science ®Google Scholar
• CLAYTON NM, SARGENT R, BUTLER A et al: The pharmacological properties of the novel selective 5-HT3R antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Motil. (1999) 11:207–217.
   PubMed Web of Science ®Google Scholar
• RAYBOULD HE, GLATZLE J, ROBIN C et al.: Expression of 5-HT3Rs by extrinsic duodenal afferents contributes to intestinal inhibition of gastric emptying.Am.Physiol Gastrointest. Liver Physiol (2003) 284:G367–G372.
   Google Scholar
• MORALES M, BATTENBERG E, BLOOM FE: Distribution of neurons expressing immunoreactivity for the 5HT3 receptor subtype in the rat brain and spinal cord. J. Comp. Nemo] (1998) 402:385–401.
   PubMed Web of Science ®Google Scholar
• WAEBER C, DIXON K, HOYER D et al.: Localisation by autoradiography of neuronal 5-HT3Rs in the mouse CNS. Eur. Pharmacol (1988) 151:351–352.
   PubMedGoogle Scholar
• KILPATRICK GJ, JONES BJ, TYERS MB: The distribution of specific binding of the 5-HT3R ligand PHIGR65630 in rat brain using quantitative autoradiography. Neurosci. Lett. (1988) 94:156–160.
   PubMedGoogle Scholar
• GEHLERT DR, GACKENHEIMER SL, WONG DT et al: Localization of 5-HT3Rs in the rat brain using PHILY278584. Brain Res. (1991) 553:149–154.
   PubMedGoogle Scholar
• ZHAI J, GERSHON MD, WALSH JH et al.: Inward currents in neurons from newborn guinea pig intestine: mediation by 5-hydroxytryptamine Type 3 receptors. Pharmacol Exp. The]: (1999) 291:374–382.
   Google Scholar
• KOCH KM, PALMER JL, NOORDIN N et al.: Sex and age differences in the pharmacokinetics of alosetron. Br. Clin. Pharmacol (2002) 53:238–242.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline: Lotronex® (Alosetron) package insert. GlaxoSmithKline, UK (2002).
   Google Scholar
• DROSSMAN DA, CAMILLERI M, MAYER EA et al: AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 123:2108–2131.
   PubMed Web of Science ®Google Scholar
• POITRAS MR, VERRIER P, SO C et al.: Group counseling psychotherapy for patients with functional gastrointestinal disorders: development of new measures for symptom severity and quality of life.Dis. Sci. (2002) 47:1297–307.
   PubMed Web of Science ®Google Scholar
• GERSHON MD: Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord. (2003) 3:S25–S34.
   Google Scholar
• •An extensive review of the roles of 5-HT3, specific 5-HT3-receptor subtypes and 5-HT3 re-uptake transporter in the enteric nervous system and the communication between the enteric nervous system and the CNS.
   Google Scholar
• XIAOPING ZHOU and JAMES J. GALLIGAN: Synaptic Activation and Properties of 5-Hydroxytryptamine3 receptors in myenteric neurons of guinea pig intestine.j Pharmacol Exp. Ther. (1999) 290:803–810.
   Google Scholar
• KADOWAKI M, NAGAKURA Y, TOMOI M et al.: Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo.Pharmacol Exp. Ther. (1993) 266:74–80.
   Google Scholar
• AXELSSON LG, WALLIN B,GILLBERG PG et al: 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats. Eur. Pharmacol (2003) 467:211–218.
   PubMedGoogle Scholar
• BUSH TG, SPENCER NJ, WATTERS N et al.: Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel M vitro. Am. I Physiol Gastrointest. Liver Physiol (2001) 281:G974–G983.
   Google Scholar
• JIN JG, FOXX-ORENSTEIN AE, GRIDER JR: Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3Rs.Pharmacol Exp. Ther. (1999) 288:93–97.
   PubMed Web of Science ®Google Scholar
• HANSEN MB, JAFFE BM: 5-HT receptor subtypes involved in luminal serotonin-induced secretion in rat intestine in vivo. Sing. Res. (1994) 56:277–287.
   Google Scholar
• TURVILL JL, CONNOR P,FARTHING MJ: The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br: J. Pharmacol (2000) 130:1031–1036.
   Google Scholar
• MOURAD FH, O'DONNELL LJ, DIAS JA et al: Role of 5-hydroxytryptamine Type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotwdns. Gut (1995) 37:340–345.
   PubMed Web of Science ®Google Scholar
• BEUBLER E, HORINA G: 5-HT2 and 5-HT3R subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology (1990) 99:83–89.
   PubMed Web of Science ®Google Scholar
• BEARCROFT CP, ANDRE EA, FARTHING MJ: In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment. Pharmacol The]: (1997) 11:1109–1114.
   Google Scholar
• VIRAMONTES BE, CAMILLERI M, MCKINZIE S et al.: Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am.j Gastroenterol (2001) 96:2671–2676.
   PubMed Web of Science ®Google Scholar
• HOUGHTON LA, FOSTER JM, WHORWELL PJ: Alosetron, a 5-HT3R antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol The]: (2000) 14:775–782.
   Google Scholar
• THUMSHIRN M, COULIE B, CAMILLERI M et al.: Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment. Pharmacol Ther. (2000) 14:869–878.
   PubMedGoogle Scholar
• CLEMENS CH, SAMSOM M, VAN BERGE HENEGOUWEN GP et al: Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol Ther. (2002) 16:993–1002.
   PubMedGoogle Scholar
• HICKS GA, COLD WELL JR, SCHINDLER M et al: Excitation of rat colonic afferent fibres by 5-HT(3) receptors. Physiol (2002) 544:861–869.
   Google Scholar
• •A study showing the existence and functionality of 5-HT3 receptors on sensory neurons in the rat lumber diagnostic-related group retrogradely labelled from the colon.
   Google Scholar
• TRAUB RJ: Evidence for thoracolumbarspinal cord processing of inflammatory, but not acute colonic pain. Neuroreport (2000) 11:2113–2116.
   PubMedGoogle Scholar
• MOSS HE, SANGER GJ: The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br. Pharmacol (1990) 100:497–501.
   PubMed Web of Science ®Google Scholar
• KOZLOWSKI CM, GREEN A, GRUNDY D et al.: The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut (2000) 46:474–480.
   PubMed Web of Science ®Google Scholar
• MIURA M, LAWSON DC, CLARY EM et al.: Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3R antagonist.Dis. sa. (1999) 44:20–24.
   Google Scholar
• MERTZ H, NALIBOFF B,MUNAKATA J et al.: Related altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology (1995) 109:40–52.
   Google Scholar
• BOUIN M, PLOURDE V, BOIVIN M et al.: Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain
   Google Scholar
• ••sensory thresholds. Gastroenterology (2002) 122:1771–1777.
   Google Scholar
• PRIOR A, READ NW: Reduction of rectalsensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol Ther: (1993) 7:175–180.
   Google Scholar
• GOLDBERG PA, KAMM MA, SETTI-CARRARO P et al: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion (1996) 57:478–483.
   PubMed Web of Science ®Google Scholar
• ZIGHELBOIM J, TALLEY NJ, PHILLIPS SF et al: Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin Type 3 antagonism. Dig. Dis. ScL (1995) 40:819–827.
   Google Scholar
• ZERBIB F, BRULEY DES VARANNES S, ORIOLA RC et al: Alosetron does not affect the visceral perception of gastric distension in healthy subjects.Aliment. Pharmacol Ther: (1994) 8:403–407.
   PubMed Web of Science ®Google Scholar
• DELVAUX M, LOUVEL D, MAMET JP et al.: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol Ther: (1998) 12:849–855.
   PubMed Web of Science ®Google Scholar
• SIMREN M, SIMMS L, D'SOUZA D et al.: Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3Rs. Aliment. Pharmacol Ther: (2003) 17:279–287.
   Google Scholar
• BERMAN SM, CHANG L,SUYENOBU B et al.: Condition-specific deactivation of brain regions by 5-HT3R antagonist alosetron. Gastroenterology (2002) 123:969–977.
   Google Scholar
• •The first study demonstrating the effect of chronic treatment of IBS patients with alosetron on brain activity. Study findings suggest that alosetron does not act as a visceroanalgesic drug.
   Google Scholar
• MAYER EA, BERMAN S,DERBYSHIRE SW et al: The effect of the 5-HT3R antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.Aliment. Pharmacol Ther: (2002) 16:1357–366.
   Google Scholar
• CAMILLERI M, MAYER EA,DROSSMAN DA et al: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3Rantagonist. Aliment. Pharmacol Ther. (1999) 13:1149–1159.
   PubMed Web of Science ®Google Scholar
• •A randomised, double-blind, placebo-controlled, dose-ranging, 12-week trial showing a beneficial effect of alosetron in the treatment of abdominal pain and discomfort in female with diarrhoea-predominant IBS.
   Google Scholar
• CAMILLERI M, NORTHCUTT AR, KONG S et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 355:1035–1040.
   PubMed Web of Science ®Google Scholar
• EDWARDS EB, HEITMAN CK, HALL P et al: A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, Phase II study to assess the clinical efficacy of alosetron (GR68755) in male subjects with irritable bowel syndrome. Am. Gastroenterol (2001) 96:S317.
   Google Scholar
• EVANS WE, RELLING MV.Pharmacogenomics: translating functional genomics into rational therapeutics.Science (1999) 15:487–491.
   Google Scholar
• HEILS A, TEUFEL A, PETRI S et al: Allelic variation of human serotonin transporter gene expression. Neurochem. (1996) 66:2621–624.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M, ATANASOVA E, CARLSON PJ et al: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 123:425–432.
   PubMed Web of Science ®Google Scholar
• •The first study providing evidence for SERT polymorphism in IBS. Such polymorphism may be related to inter-individual differences in sensitivity to 5-HT3 receptor modulating drugs.
   Google Scholar
• VELDHUYZEN VAN ZANTEN SJ, TALLEY NJ, BYTZER P et al: Design of treatment trials for functional gastrointestinal disorders. Gut (1999) 45(II):69–77.
   Google Scholar
• EL-SERAG HB, OLDEN K,BJORKMAN D: Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment. Pharmacol Ther. (2002) 16:1171–1185.
   PubMed Web of Science ®Google Scholar
• FITZPATRICK R, FLETCHER A, GORE S et al: Quality of life measures in health care. I: Applications and issues in assessment. Br. Med. (1992) 305:1074–077.
   PubMed Web of Science ®Google Scholar
• WATSON ME, LACEY L, KONG S et al:Alosetron improves quality of life in womenwith diarrhea-predominant irritable bowelsyndrome. Am. Gastroenterol (2001) 96:455–459.
   PubMed Web of Science ®Google Scholar
• HAHN BA, KIRCHDOERFER LJ, FULLERTON S et al.: Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life.Aliment. Pharmacol Ther. (1997) 11:553–559.
   PubMed Web of Science ®Google Scholar
• WOLFE SG, CHEY WY,WASHINGTON MK et al: Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am. Gastroenterol (2001) 96:803–811.
   PubMed Web of Science ®Google Scholar
• ••A multi-centre, randomised, double-blind,placebo-controlled study assessing the safety and tolerability of treatment with alosetron 1 mg b.i.d. for 48 weeks in female and male patients with IBS.
   Google Scholar
• MOYNIHAN R: Alosetron: a case study in regulatory capture, or a victory for patients' rights? Br. Med. (2002) 325:592–595.
   Google Scholar
• HORTON R: Lotronex and the FDA: a fatal erosion of integrity. Lancet (2001) 357:1544–1545.
   PubMed Web of Science ®Google Scholar
• FRIEDEL D, THOMAS R, FISHER RS:Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 120:557–560.
   PubMed Web of Science ®Google Scholar
• LADABAUM U: Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment. Pharmacol Ther: (2003) 17:1021–1030.
   PubMedGoogle Scholar
• ••An analysis of the published literatureaimed to examine the balance between alosetron's efficacity and safety and evaluation of the alosetron's cost-effectiveness. The study shows a favourable balance between benefits and risks associated with the use of alosetron and a substantial cost/QALY gained.Affiliation
   Google Scholar